Urokinase receptor and integrin interactions

Current Pharmaceutical Design

Volumn 9, Issue 19, 2003, Pages 1565-1574

  Kugler, Matthias C ^a   Wei, Ying ^a   Chapman, Harold A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adhesion; Integrin; Receptor; Urokinase

Indexed keywords

CIS ACTING ELEMENT; GLYCOLIPID; INTEGRIN; LIGAND; MEMBRANE PROTEIN; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR; UROKINASE; UROKINASE RECEPTOR;

BREAST CANCER; CELL ADHESION; CELL MIGRATION; CELL SURFACE; COMPLEX FORMATION; HUMAN; IN VIVO STUDY; METASTASIS; MOLECULAR MECHANICS; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS;

AMINO ACID SEQUENCE; ANIMALS; HUMANS; INTEGRINS; MOLECULAR SEQUENCE DATA; RECEPTORS, CELL SURFACE; SEQUENCE ANALYSIS, PROTEIN;

EID: 0038643516     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612033454658     Document Type: Review

References (111)

1. Chapman; H. A.; Jr.; Vavrin; Z.; Hibbs; J. B.; Jr. Macrophage fibrinolytic activity: identification of two pathways of plasmin formation by intact cells and of a plasminogen activator inhibitor. Cell 1982, 28, 653-662.
2. Blasi; F.; Vassalli JD; Dano K. Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors. J. Cell Biol. 1987, 104, 801-804.
3. Blasi, F. Urokinase and urokinase receptor: a paracrine/autocrine system regulating cell migration and invasiveness. Bioessays 1993, 15, 105-111.
4. Roldan; A.; Cubellis MV; Masucci MT; Behrendt N; Lund LR; Dano K; Appella E; Blasi F. Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. EMBO J. 1990, 9, 467-474.
5. Bugge; T.; Flick MJ; Danton MJ; Daugherty CC; Romer J; Dano K; Carmeliet P; Collen D; Degen JL. Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator. Proc. Natl. Acad. Sci. U. S. A. 1996, 93, 5899-5904.
6. Bdeir; K.; Murciano JC; Tomaszewski J; Koniaris L; Martinez J; Cines DB; Muzykantov VR; Higazi AA. Urokinase mediates fibrinolysis in the pulmonary microvasculature. Blood 2000, 1820-1826.
7. Ninomiya; H.; Hasegawa Y; Nagasawa T; Abe T. Excess soluble urokinase-type plasminogen activator receptor in the plasma of patients with paroxysmal nocturnal hemoglobinuria inhibits cell-associated fibrinolytic activity. Int. J. Hematol. 1997, 65, 285-291.
8. Ploug; M.; Plesner T; Ronne E; Ellis V; Hoyer-Hansen G; Hansen NE; Dano K. The receptor for urokinase-type plasminogen activator is deficient on peripheral blood leukocytes in patients with paroxysmal nocturnal hemoglobinuria. Blood 1992, 79, 1447-1455.
9. Gudewicz, P. W.; Gilboa, N. Human urokinase-type plasminogen activator stimulates chemotaxis of human neutrophils. Biochem. Biophys. Res. Commun. 1987, 147, 1176-1181.
10. Waltz, D. A.; Sailor, L. Z.; Chapman, H. A. Cytokines induce urokinase-dependent adhesion of human myeloid cells. A regulatory role for plasminogen activator inhibitors. J. Clin. Invest. 1993, 91, 1541-1552.
11. Nusrat, A. R.; Chapman, H. A., Jr. An autocrine role for urokinase in phorbol ester-mediated differentiation of myeloid cell lines. J. Clin. Invest. 1991, 87, 1091-1097.
12. Stahl, A.; Mueller, B. M. Melanoma cell migration on vitronectin: regulation by components of the plasminogen activation system. Int. J. Cancer 1997, 71, 116-122.
13. Wei, Y.; Waltz, D. A.; Rao, N.; Drummond, R. J.; Rosenberg, S. et al. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J. Biol. Chem. 1994, 269, 32380-32388.
14. Del Rosso, M.; Pucci, M.; Fibbi, G.; Dini, G. Interaction of urokinase with specific receptors abolishes the time of commitment to terminal differentiation of murine erythroleukaemia (Friend) cells. Br. J. Haematol. 1987, 66, 289-294.
15. Fibbi, G.; Magnelli, L.; Pucci, M.; Del Rosso, M. Interaction of urokinase A chain with the receptor of human keratinocytes stimulates release of urokinase-like plasminogen activator. Exp. Cell Res. 1990, 187, 33-38.
16. Blasi, F.; Carmeliet, P. uPAR: a versatile signalling orchestrator. Nature Rev. Mol. Cell Biol. 2002, 3, 932-943.
17. Kjoller, L. The urokinase plasminogen activator receptor in the regulation of the actin cytoskeleton and cell motility. Biol. Chem. 2002, 383, 5-19.
18. Ossowski, L.; Aguirre-Ghiso, J. A. Urokinase receptor and integrin partnership: coordination of signaling for cell adhesion, migration and growth. Curr. Opin. Cell Biol. 2000, 12, 613-620.
19. Pollanen, J.; Hedman, K.; Nielsen, L. S.; Dano, K.; Vaheri, A. Ultrastructural localization of plasma membrane-associated urokinase-type plasminogen activator at focal contacts. J. Cell Biol. 1988, 106, 87-95.
20. Hedberg, K. K.; Stauff, C.; Hoyer-Hansen, G.; Ronne, E.; Griffith, O. H. High-molecular-weight serum protein complexes differentially promote cell migration and the focal adhesion localization of the urokinase receptor in human glioma cells. Exp. Cell Res. 2000, 257, 67-81.
21. Limongi, P.; Resnati, M.; Hernandez-Marrero, L.; Cremona, O.; Blasi, F. et al. Biosynthesis and apical localization of the urokinase receptor in polarized MDCK epithelial cells. FEBS Lett. 1995, 369, 207-211.
22. Myohanen, H. T.; Stephens, R. W.; Hedman, K.; Tapiovaara, H.; Ronne, E. et al. Distribution and lateral mobility of the urokinase-receptor complex at the cell surface. J. Histochem. Cytochem. 1993, 41, 1291-1301.
23. Schwab, W.; Gavlik, J. M.; Beichler, T.; Funk, R. H.; Albrecht, S. et al. Expression of the urokinase-type plasminogen activator receptor in human articular chondrocytes: association with caveolin and beta 1-integrin. Histochem. Cell Biol. 2001, 115, 317-323.
24. Wei, Y.; Eble, J. A.; Wang, Z.; Kreidberg, J. A.; Chapman, H. A. Urokinase receptors promote betal integrin function through interactions with integrin alpha3beta1. Mol. Biol. Cell 2001, 12, 2975-2986.
25. Xue, W.; Kindzelskii, A. L.; Todd, R. F., 3rd; Petty, H. R. Physical association of complement receptor type 3 and urokinase-type plasminogen activator receptor in neutrophil membranes. J. Immunol. 1994, 152, 4630-4640.
26. Xue, W.; Mizukami, I.; Todd, R. F., 3rd; Petty, H. R. Urokinase-type plasminogen activator receptors associate with beta1 and beta3 integrins of fibrosarcoma cells: dependence on extracellular matrix components. Cancer Res. 1997, 57, 1682-1689.
27. Kindzelskii, A. L.; Eszes, M. M.; Todd, R. F., 3rd; Petty, H. R. Proximity oscillations of complement type 4 (alphaX beta2) and urokinase receptors on migrating neutrophils. Biophys. J. 1997, 73, 1777-1784.
28. Kindzelskii, A. L.; Laska, Z. O.; Todd, R. F., 3rd; Petty, H. R. Urokinase-type plasminogen activator receptor reversibly dissociates from complement receptor type 3 (alpha M beta 2′ CD11b/CD18) during neutrophil polarization. J. Immunol. 1996, 156, 297-309.
29. Xia, Y.; Borland, G.; Huang, J.; Mizukami, I. F.; Petty, H. R. et al. Function of the lectin domain of Mac-1/complement receptor type 3 (CD11b/CD18) in regulating neutrophil adhesion. J. Immunol. 2002, 169, 6417-6426.
30. Aguirre Ghiso, J. A.; Kovalski, K.; Ossowski, L. Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J. Cell Biol. 1999, 147, 89-104.
31. Ghosh, S.; Brown, R.; Jones, J. C.; Ellerbroek, S. M.; Stack, M. S. Urinary-type plasminogen activator (uPA) expression and uPA receptor localization are regulated by alpha 3beta 1 integrin in oral keratinocytes. J. Biol. Chem. 2000, 275, 23869-23876.
32. Simon, D. I.; Wei, Y.; Zhang, L.; Rao, N. K.; Xu, H. et al. Identification of a urokinase receptor-integrin interaction site. Promiscuous regulator of integrin function. J. Biol. Chem. 2000, 275, 10228-10234.
33. Wei, Y.; Yang, X.; Liu, Q.; Wilkins, J. A.; Chapman, H. A. A role for caveolin and the urokinase receptor in integrin-mediated adhesion and signaling. J. Cell Biol. 1999, 144, 1285-1294.
34. Yebra, M.; Goretzki, L.; Pfeifer, M.; Mueller, B. M. Urokinase-type plasminogen activator binding to its receptor stimulates tumor cell migration by enhancing integrin-mediated signal transduction. Exp. Cell Res. 1999, 250, 231-240.
35. Tarui, T.; Mazar, A. P.; Cines, D. B.; Takada, Y. Urokinase-type plasminogen activator receptor (CD87) is a ligand for integrins and mediates cell-cell interaction. J. Biol. Chem. 2001, 276, 3983-3990.
36. Aguirre Ghiso, J. A. Inhibition of FAK signaling activated by urokinase receptor induces dormancy in human carcinoma cells in vivo. Oncogene 2002, 21, 2513-2524.
37. Liu, D.; Aguirre Ghiso, J.; Estrada, Y.; Ossowski, L. EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma. Cancer Cell 2002, 1, 445-457.
38. Fong, S.; Doyle, M. V.; Goodson, R. J.; Drummond, R. J.; Stratton, J. R. et al. Random peptide bacteriophage display as a probe for urokinase receptor ligands. Biol. Chem. 2002, 383, 141-158.
39. van der Pluijm, G.; Sijmons, B.; Vloedgraven, H.; van der Bent, C.; Drijfhout, J. W. et al. Urokinase-receptor/integrin complexes are functionally involved in adhesion and progression of human breast cancer in vivo. Am. J. Pathol. 2001, 159, 971-982.
40. Wei, Y.; Lukashev, M.; Simon, D. I.; Bodary, S. C.; Rosenberg, S. et al. Regulation of integrin function by the urokinase receptor. Science 1996, 273, 1551-1555.
41. Xiong, J. P.; Stehle, T.; Diefenbach, B.; Zhang, R.; Dunker, R. et al. Crystal structure of the extracellular segment of integrin alpha Vbeta3. Science 2001, 294, 339-345.
42. Springer, T. Folding of the N-terminal, ligand-binding region of integrin alpha-subunits into a beta-propeller domain. Proc. Natl. Acad. Sci. USA 1997, 94, 65-72.
43. Xiong, J. P.; Stehle, T.; Zhang, R.; Joachimiak, A.; Frech, M. et al. Crystal structure of the extracellular segment of integrin alpha Vbeta3 in complex with an Arg-Gly-Asp ligand. Science 2002, 296, 151-155.
44. Zhang XP, P.-M. W., Irie A, Kovach N, Prokopishyn NL, Laferte S, Takeuchi K, Tsuji T, Takada Y. Alpha 3 beta 1 adhesion to laminin-5 and invasin: critical and differential role of integrin residues clustered at the boundary between alpha 3 N-terminal repeats 2 and 3. Biochemistry 1999, 38, 14424-14431.
45. Hynes, R. O. Integrins: bidirectional, allosteric signaling machines. Cell 2002, 110, 673-687.
46. Takagi, J.; Petre, B. M.; Walz, T.; Springer, T. A. Global conformational rearrangements in integrin extracellular domains in outside-in and inside-out signaling. Cell 2002, 110, 599-611.
47. Takagi, J.; Springer, T. A. Integrin activation and structural rearrangement. Immunol. Rev. 2002, 186, 141-163.
48. Pyke, C.; Salo, S.; Ralfkiaer, E.; Romer, J.; Dano, K. et al. Laminin-5 is a marker of invading cancer cells in some human carcinomas and is coexpressed with the receptor for urokinase plasminogen activator in budding cancer cells in colon adenocarcinomas. Cancer Res. 1995, 55, 4132-4139.
49. Fukushima, Y., Ohnishi T, Arita N, Hayakawa T, Sekiguchi K. Integrin alpha3 beta1-mediated interaction with laminin-5 stimulates adhesion, migration and invasion of malignant glioma cells. Int. J. Cancer 1998, 76, 63-72.
50. Tsuj, T., Kawada Y, Kai-Murozono M, Komatsu S, Han SA, Takeuchi K, Mizushima H, Miyazaki K, Irimura T. Regulation of melanoma cell migration and invasion by laminin-5 and alpha3beta1 integrin (VLA-3). Clin. Exp. Metastasis 2002, 19, 127-134.
51. Eble, J., Wucherpfennig KW, Gauthier L, Dersch P, Krukonis E, Isberg RR, Hemler ME. Recombinant soluble human alpha 3 beta 1 integrin: purification, processing, regulation, and specific binding to laminin-5 and invasin in a mutually exclusive manner. Biochemistry 1998, 37, 10945-10955.
52. Pluskota, E.; Soloviev, D. A.; Plow, E. F. Convergence of the adhesive and fibrinolytic systems: recognition of urokinase by integrin {alpha}M {beta}2 as well as the urokinase receptor regulates cell adhesion and migration. Blood 2002, 26, 26.
53. Hodivala-Dilke, K. M.; DiPersio, C. M.; Kreidberg, J. A.; Hynes, R. O. Novel roles for alpha3beta1 integrin as a regulator of cytoskeletal assembly and as a trans-dominant inhibitor of integrin receptor function in mouse keratinocytes. J. Cell Biol. 1998, 142, 1357-1369.
54. Resnati, M.; Pallavicini, I.; Wang, J. M.; Oppenheim, J.; Serhan, C. N. et al. The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R. Proc. Natl. Acad. Sci. USA 2002, 99, 1359-1364.
55. Adachi, Y.; Lakka, S. S.; Chandrasekar, N.; Yanamandra, N.; Gondi, C. S. et al. Down-regulation of integrin alpha(v)beta(3) expression and integrin-mediated signaling in glioma cells by adenovirus-mediated transfer of antisense urokinase-type plasminogen activator receptor (uPAR) and sense p16 genes. J. Biol. Chem. 2001, 276, 47171-47177.
56. Carriero, M. V.; Del Vecchio, S.; Capozzoli, M.; Franco, P.; Fontana, L. et al. Urokinase receptor interacts with alpha(v)beta5 vitronectin receptor, promoting urokinase-dependent cell migration in breast cancer. Cancer Res. 1999, 59, 5307-5314.
57. Degryse, B.; Orlando, S.; Resnati, M.; Rabbani, S. A.; Blasi, F. Urokinase/urokinase receptor and vitronectin/alpha(v)beta(3) integrin induce chemotaxis and cytoskeleton reorganization through different signaling pathways. Oncogene 2001, 20, 2032-2043.
58. Hapke, S.; Kessler, H.; Arroyo de Prada, N.; Benge, A.; Schmitt, M. et al. Integrin alpha(v)beta(3)/vitronectin interaction affects expression of the urokinase system in human ovarian cancer cells. J. Biol. Chem. 2001, 276, 26340-26348.
59. Khatib, A. M.; Nip, J.; Fallavollita, L.; Lehmann, M.; Jensen, G. et al. Regulation of urokinase plasminogen activator/plasmin-mediated invasion of melanoma cells by the integrin vitronectin receptor alphaVbeta3. Int. J. Cancer 2001, 91, 300-308.
60. Nguyen, D. H.; Catling, A. D.; Webb, D. J.; Sankovic, M.; Walker, L. A. et al. Myosin light chain kinase functions downstream of Ras/ERK to promote migration of urokinase-type plasminogen activator-stimulated cells in an integrin-selective manner. J. Cell Biol. 1999, 146, 149-164.
61. Nip, J.; Rabbani, S. A.; Shibata, H. R.; Brodt, P. Coordinated expression of the vitronectin receptor and the urokinase- type plasminogen activator receptor in metastatic melanoma cells. J. Clin. Invest. 1995, 95, 2096-2103.
62. Jo, M.; Thomas, K. S.; Somlyo, A. V.; Somlyo, A. P.; Gonias, S. L. Cooperativity between the Ras-ERK and Rho-Rho kinase pathways in urokinase-type plasminogen activator-stimulated cell migration. J. Biol. Chem. 2002, 277, 12479-12485.
63. Hapke, S.; Gawaz, M.; Dehne, K.; Kohler, J.; Marshall, J. F. et al. beta(3)A-integrin downregulates the urokinase-type plasminogen activator receptor (u-PAR) through a PEA3/ets transcriptional silencing element in the u-PAR promoter. Mol. Cell Biol. 2001, 21, 2118-2132.
64. Besta, F.; Massberg, S.; Brand, K.; Muller, E.; Page, S. et al. Role of beta(3)-endonexin in the regulation of NF-kappaB-dependent expression of urokinase-type plasminogen activator receptor. J. Cell Sci. 2002, 115, 3879-3888.
65. Klemke; R.; Yebra M; Bayna EM; Cheresh DA. Receptor tyrosine kinase signaling required for integrin alpha v beta 5-directed cell motility but not adhesion on vitronectin. J. Cell Biol. 1994, 127, 859-866.
66. Yebra, M.; Parry, G. C.; Stromblad, S.; Mackman, N.; Rosenberg, S. et al. Requirement of receptor-bound urokinase-type plasminogen activator for integrin alphavbeta5-directed cell migration. J. Biol. Chem. 1996, 271, 29393-29399.
67. Chapman, H.; Wei Y. Protease crosstalk with integrins: the urokinase receptor paradigm. Thromb. Haemost. 2001, 86, 124-129.
68. Chang, A. W.; Koo, A.; Barnathan, E. S.; Okada, S. S. Urokinase receptor-dependent upregulation of smooth muscle cell adhesion to vitronectin by urokinase. Arterioscler. Thromb. Vasc. Biol. 1998, 18, 1855-1860.
69. Andreasen, P. A.; Egelund, R.; Petersen, H. H. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol. Life Sci. 2000, 57, 25-40.
70. Schafer, K.; Konstantinides, S.; Riedel, C.; Thinnes, T.; Muller, K. et al. Different mechanisms of increased luminal stenosis after arterial injury in mice deficient for urokinase- or tissue-type plasminogen activator. Circulation 2002, 106, 1847-1852.
71. Suelves, M.; Lopez-Alemany, R.; Lluis, F.; Aniorte, G.; Serrano, E. et al. Plasmin activity is required for myogenesis in vitro and skeletal muscle regeneration in vivo. Blood 2002, 99, 2835-2844.
72. Lluis, F.; Roma, J.; Suelves, M.; Parra, M.; Aniorte, G. et al. Urokinase-dependent plasminogen activation is required for efficient skeletal muscle regeneration in vivo. Blood 2001, 97, 1703-1711.
73. Li, Y.; Knisely, J. M.; Lu, W.; McCormick, L. M.; Wang, J. et al. Low Density Lipoprotein (LDL) Receptor-related Protein 1B Impairs Urokinase Receptor Regeneration on the Cell Surface and Inhibits Cell Migration. J. Biol. Chem. 2002, 277, 42366-42371.
74. Weaver VM; P. O.; Wang F; Larabell CA; Briand P; Damsky C; Bissell MJ. Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. J. Cell Biol. 1997, 137, 231-245.
75. Czekay R.-P.; K. A.; S.A. Curriden; D.J. Loskutoff Plasminogen Activator Inhibitor-1 Detaches Cells from Extracellular Matrices by Inactivating Integrins. J. Cell Biol. 2003.
76. Carmeliet, P.; Schoonjans, L.; Kieckens, L.; Ream, B.; Degen, J. et al. Physiological consequences of loss of plasminogen activator gene function in mice. Nature 1994, 368, 419-424.
77. Bugge, T. H.; Suh, T. T.; Flick, M. J.; Daugherty, C. C.; Romer, J. et al. The receptor for urokinase-type plasminogen activator is not essential for mouse development or fertility. J. Biol. Chem. 1995, 270, 16886-16894.
78. Dewerchin, M.; Nuffelen, A. V.; Wallays, G.; Bouche, A.; Moons, L. et al. Generation and characterization of urokinase receptor-deficient mice. J. Clin. Invest. 1996, 97, 870-878.
79. Couffinhal, T.; Duplaa, C.; Moreau, C.; Lamaziere, J. M.; Bonnet, J. Regulation of vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 in human vascular smooth muscle cells. Circulation Res. 1994, 74, 225-234.
80. Springer, T. A. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994, 76, 301-314.
81. Gyetko, M. R.; Sud, S.; Kendall, T.; Fuller, J. A.; Newstead, M. W. et al. Urokinase receptor-deficient mice have impaired neutrophil recruitment in response to pulmonary Pseudomonas aeruginosa infection. J. Immunol. 2000, 165, 1513-1519.
82. Rijneveld, A. W.; Levi, M.; Florquin, S.; Speelman, P.; Carmeliet, P. et al. Urokinase receptor is necessary for adequate host defense against pneumococcal pneumonia. J. Immunol. 2002, 168, 3507-3511.
83. Waltz, D. A.; Natkin, L. R.; Fujita, R. M.; Wei, Y.; Chapman, H. A. Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin. J. Clin. Invest. 1997, 100, 58-67.
84. May, A. E.; Kanse, S. M.; Lund, L. R.; Gisler, R. H.; Imhof, B. A. et al. Urokinase receptor (CD87) regulates leukocyte recruitment via beta 2 integrins in vivo. J. Exp. Med. 1998, 188, 1029-1037.
85. Wagner, J. G.; Roth, R. A. Neutrophil migration mechanisms, with an emphasis on the pulmonary vasculature 1. Pharmacol. Rev. 2000, 52, 349-374.
86. Gyetko, M. R.; Sud, S.; Sonstein, J.; Polak, T.; Sud, A. et al. Antigen-driven lymphocyte recruitment to the lung is diminished in the absence of urokinase-type plasminogen activator (uPA) receptor, but is independent of uPA. J. Immunol. 2001, 167, 5539-5542.
87. Bianchi, E.; Ferrero, E.; Fazioli, F.; Mangili, F.; Wang, J. et al. Integrin-dependent induction of functional urokinase receptors in primary T lymphocytes. J. Clin. Invest. 1996, 98, 1133-1141.
88. Chin, J. E.; Hatfield, C. A.; Winterrowd, G. E.; Brashler, J. R.; Vonderfecht, S. L. et al. Airway recruitment of leukocytes in mice is dependent on alpha4-integrins and vascular cell adhesion molecule-1. Am. J. Phys. 1997, 272, L219-L229.
89. Wolber, F. M.; Curtis, J. L.; Maly, P.; Kelly, R. J.; Smith, P. et al. Endothelial selectins and alpha4 integrins regulate independent pathways of T lymphocyte recruitment in the pulmonary immune response. J. Immunol. 1998, 161, 4396-4403.
90. May, A. E.; Schmidt, R.; Kanse, S. M.; Chavakis, T.; Stephens, R. W. et al. Urokinase receptor surface expression regulates monocyte adhesion in acute myocardial infarction. Blood 2002, 100, 3611-3617.
91. Andreasen, P.; Kjoller, L.; Christensen, E. I.; Duffy, M. J. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int. J. Cancer 1997, 72, 1-22.
92. Christofori, G.; Semb, H. The role of the cell-adhesion molecule E-cadherin as a tumour- suppressor gene. Trends Biochem Sci. 1999, 24, 73-76.
93. Giancotti, F. G.; Ruoslahti, E. Integrin signaling. Science 1999, 285, 1028-1032.
94. Schmitt, M.; Wilhelm, O. G.; Reuning, U.; KrÅger, A.; Harbeck, N. et al. The urokinase plasminogen activator system as a novel target for tumor therapy. Fibrinol. Proteol. 2000, 14, 114-132.
95. Aguirre-Ghiso, J. A.; Liu, D.; Mignatti, A., Kovalski, K.; Ossowski, L. Urokinase receptor and fibronectin regulate the ERK(MAPK) to p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo. Mol. Biol. Cell 2001, 12, 863-879.
96. Liu, Z. X.; Yu, C. F.; Nickel, C.; Thomas, S.; Cantley, L. G. Hepatocyte growth factor induces ERK-dependent paxillin phosphorylation and regulates paxillin-focal adhesion kinase association. J. Biol. Chem. 2002, 277, 10452-10458.
97. Kook, Y. H.; Adamski, J.; Zelent, A.; Ossowski, L. The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy. EMBO J. 1994, 13, 3983-3991.
98. Carmeliet, P.; Moons, L.; Dewerchin, M.; Rosenberg, S.; Herbert, J. M. et al. Receptor-independent role of urokinase-type plasminogen activator in pericellular plasmin and matrix metalloproteinase proteolysis during vascular wound healing in mice. J. Cell Biol. 1998, 140, 233-245.
99. Swaisgood, C. M.; French, E. L.; Noga, C.; Simon, R. H.; Ploplis, V. A. The development of bleomycin-induced pulmonary fibrosis in mice deficient for components of the fibrinolytic system. Am. J. Pathol. 2000, 157, 177-187.
100. Lazarovits, A. I.; Karsh, J. Differential expression in rheumatoid synovium and synovial fluid of alpha 4 beta 7 integrin. A novel receptor for fibronectin and vascular cell adhesion molecule-1. J. Immunol. 1993, 151, 6482-6489.
101. McMurray, R. W.; Tang, H.; Braley-Mullen, H. The role of alpha 4 integrin and intercellular adhesion molecule-1 (ICAM-1) in murine experimental autoimmune thyroiditis. Autoimmunity 1996, 23, 9-23.
102. Theien, B. E.; Vanderlugt, C. L.; Eagar, T. N.; Nickerson-Nutter, C.; Nazareno, R. et al. Discordant effects of anti-VLA-4 treatment before and after onset of relapsing experimental autoimmune encephalomyelitis. J. Clin. Invest. 2001, 107, 995-1006.
103. Chia, M. C. The role of adhesion molecules in atherosclerosis. Crit. Rev. Clin. Lab. Sci. 1998, 35, 573-602.
104. Kling, D.; Fingerle, J.; Harlan, J. M.; Lobb, R. R.; Lang, F. Mononuclear leukocytes invade rabbit arterial intima during thickening formation via CD18-and VLA-4-dependent mechanisms and stimulate smooth muscle migration. Circ. Res. 1995, 77, 1121-1128.
105. Sanders, M. Molecular and cellular concepts in atherosclerosis. Pharmacol. Ther. 1994, 61, 109-153.
106. Thomas, G. J.; Hart, I. R.; Speight, P. M.; Marshall, J. F. Binding of TGF-betal latency-associated peptide (LAP) to alpha(v)beta6 integrin modulates behaviour of squamous carcinoma cells. Br. J. Cancer 2002, 87, 859-867.
107. Ossowski, L.; Aguirre Ghiso, J.; Liu, D.; Yu, W.; Kovalski, K. The role of plasminogen activator receptor in cancer invasion and dormancy. Medicina (B Aires) 1999, 59, 547-552.
108. Van der Velde-Zimmerman, D.; Smits, A. J.; Verdaasdonk, M. A.; Rademakers, L. H.; Werner, N. et al. beta1-Integrins dominate cell traffic of leukemic cells in human bone-marrow stroma. Int. J. Cancer 1996, 66, 225-233.
109. Blum, J. E. and Handmaker, H. Small peptide radiopharmaceuticals in the imaging of acute thrombus. Curr. Pharm. Des. 2002, 8(20), 1815-26.
110. Jackson, D. Y. Alpha 4 integrin antagonists. Curr. Pharm. Des. 2002, 8(14), 1229-53.
111. Rockway, T. W.; Nienaber, V. and Giranda, V. L. Inhibitors of the protease domain of urokinase-type plasminogen activator. Curr. Pharm. Des. 2002, 8(28), 2541-58.